Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

APIXABAN

All products: general benefit

Other products in the same Health Canada class (B01A, B01AF) — coverage varies; not interchangeable

  • Edoxaban (Lixiana): general benefit
  • Rivaroxaban (Xarelto): general benefit
  • Dabigatran etexilate (Pradaxa): general benefit, Not a benefit
  • Enoxaparin (Noromby): general benefit
  • Warfarin (Coumadin): general benefit, Not a benefit
  • Dalteparin (Fragmin): limited Use 186, 187, 188, 189

5 more in the class list below

Eliquis · DIN 02377233 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists ELIQUIS (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Eliquis · DIN 02377233 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2013-08-29 Health Canada: Marketed since 2012-02-01 · brand ELIQUIS · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86287 · Verify on the e-Formulary ↗ (DIN 02377233)

Source record
DIN 02377233: Eliquis Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id BQU Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.6336; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02377233 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86287
Interchangeable products
Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (20:12 Coagulants and Anti-Coagulants) and how they are covered

Matched class: 20:12 Coagulants and Anti-Coagulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ENOXAPARIN, RIVAROXABAN Some products covered without a code (check the product listing): DABIGATRAN ETEXILATE, EDOXABAN, WARFARIN 20:12 Coagulants and Anti-Coagulants

RIVAROXABAN

· 48 products · General benefit · strengths: 2.5mg, 10mg, 15mg, 20mg · Tab

DABIGATRAN ETEXILATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (4) · strengths: 75mg, 110mg, 150mg · Cap

ENOXAPARIN

· 37 products · General benefit · strengths: 20mg/0.2mL, 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 120mg/0.8mL, 100mg/mL, 150mg/mL, 300mg/3mL · Inj Sol-0.2mL Pref Syr (Preservative-Free), Inj Sol-0.3mL Pref Syr (Preservative-Free), Inj Sol-0.4mL Pref Syr (Preservative-Free), Inj Sol-0.6mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-3mL Vial Pk (With Preservative)

WARFARIN

· 23 products · Listed, not a benefit (8), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (1) · strengths: 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 10mg · Tab

DALTEPARIN SODIUM

· 10 products · Limited Use, codes 186, 187, 188, 189 · strengths: 3500IU/0.28mL, 7500IU/0.3mL, 2500IU/0.2mL, 5000IU/0.2mL, 10000IU/0.4mL, 12500IU/0.5mL, 15000IU/0.6mL, 18000IU/0.72mL, 16500IU/0.66mL, 25000IU/mL · Inj Pref Syr, Inj Pref Syr-0.66mL Pk, Multidose 3.8mL Pk

FONDAPARINUX SODIUM

· 4 products · Limited Use, codes 378 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 2.5mg/0.5mL, 7.5mg/0.6mL · Inj Sol-Pref Syr 0.5mL Pk (Preservative Free), Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)

NADROPARIN CALCIUM

· 7 products · Limited Use, codes 186, 187, 188, 189 · strengths: 9500IU/mL, 19000IU/mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-0.8mL Pk, Pref Syr-1.0mL Pk

TICAGRELOR

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (5), Limited Use, codes 441 (5) · strengths: 60mg, 90mg · Tab

TINZAPARIN SODIUM

· 11 products · Limited Use, codes 186, 187, 188, 189, 323 · strengths: 2500IU/0.25mL, 8000IU/0.4mL, 12000IU/0.6mL, 16000IU/0.8mL, 3500IU/0.35mL, 4500IU/0.45mL, 10000IU/0.5mL, 14000IU/0.7mL, 18000IU/0.9mL, 10000IU/mL, 20000IU/mL · Inj Pref Syr, Inj-2mL Pk

EPTIFIBATIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.75mg/mL, 2mg/mL · 100mL Vial Pk, 10mL Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12 20:12:04 Direct Factor Xa Inhibitors

EDOXABAN

· 11 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) · strengths: 15mg, 30mg, 60mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:04 20:12:16 Hemostatics

TRANEXAMIC ACID

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:16 Hematopoietic Agents, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: venous thromboembolic events
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: RIVAROXABAN RIVAROXABAN · General benefit Indications XARELTO® (rivaroxaban) film-coated tablet (10 mg, 15 mg, 20 mg) is indicated for the: • prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery. PM: https://pdf.hres.ca/dpd_pm/00082020.PDF; date 2025-09-23; DIN 02316986; fetched 2026-09-10 Product monograph XARELTO® (rivaroxaban) granules for oral suspension (1mg/mL) is indicated for the: • treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment (see 4 Dosage and Administration). PM: https://pdf.hres.ca/dpd_pm/00082020.PDF; date 2025-09-23; DIN 02316986; fetched 2026-09-10 Product monograph XARELTO® (rivaroxaban) film-coated tablet (15 mg) is indicated for the: • treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment (see 4 Dosage and Administration). PM: https://pdf.hres.ca/dpd_pm/00082020.PDF; date 2025-09-23; DIN 02316986; fetched 2026-09-10 Product monograph XARELTO® (rivaroxaban) film-coated tablet (20 mg) is indicated for the: • treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment (see 4 Dosage and Administration). PM: https://pdf.hres.ca/dpd_pm/00082020.PDF; date 2025-09-23; DIN 02316986; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ELIQUIS (apixaban) is indicated for: • the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective knee or hip replacement surgery. • the prevention of stroke and systemic embolism in patients with atrial fibrillation . • the treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE. Geriatrics (≥ 65 years of age) Clinical studies in VTE prevention, stroke prevention in patients with atrial fibrillation (SPAF), treatment of DVT and PE, and prevention of recurrent DVT and PE included patients ≥ 65 years of age (see WARNINGS AND PRECAUTIONS, Renal Impairment, DOSAGE AND ADMINISTRATION, and CLINICAL TRIALS). Pediatrics (< 18 years of age) The safety and efficacy of ELIQUIS in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use. Pharmacokinetic / Pr ELIQUIS (apixaban) Product Monograph Page 3 of 84 pharmacodynamic data are available from a single-dose pediatric study (28 d… https://pdf.hres.ca/dpd_pm/00078262.PDF PM date: JAN 10, 2025 Source product: ELIQUIS; DIN 02377233; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.